Skip to main content

Table 3 Associations between the clinical and laboratory characteristics of the patients and SMFS in univariate and multivariate logistic regression analysis

From: Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma

Characteristic Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age (≥ 45 vs. < 45 years) 1.288 1.008–1.647 0.043    
Gender (Male vs. Female) 0.867 0.635–1.184 0.371    
Smoking Status (Present vs. Absent) 1.120 0.871–1.440 0.376    
Drinking Status (Present vs. Absent) 0.911 0.615–1.349 0.642    
Family history (Present vs. Absent) 0.831 0.627–1.010 0.198    
Calcium, mmol/L (≥ 2.4 vs. < 2.4) 0.927 0.725–1.186 0.548    
Phosphorus, mmol/L (≥ 1.15 vs. < 1.15) 0.927 0.725–1.185 0.545    
Magnesium, mmol/L (≥ 0.93 vs. < 0.93) 0.804 0.552–1.172 0.257    
CRP, mg/L (≥ 1.91 vs. < 1.91) 2.092 1.618–2.706 < 0.001 1.450 1.108–1.897 0.007
WBCs, ×109 (≥ 6.9 vs. < 6.9) 1.050 0.822–1.342 0.694    
Neutrophils, ×109 (≥ 4.2 vs. < 4.2) 1.177 0.921–1.504 0.193    
HGB, g/L (≥ 145 vs. < 145) 0.835 0.653–1.068 0.150    0.023
Platelets, ×109 (≥ 229 vs. < 229) 1.134 0.887–1.449 0.315    
ALT, U/L (≥ 22.2 vs. < 22.2) 0.971 0.760–1.241 0.814    
AST, U/L (≥ 21 vs. < 21) 1.283 1.003–1.641 0.047    
ALP, U/L (≥ 70 vs. < 70) 2.023 1.570–2.606 < 0.001 1.654 1.275–2.145 < 0.001
LDH, U/L (≥ 172.2 vs. < 172.2) 1.951 1.514–2.514 < 0.001 1.424 1.098–1.847 < 0.001
ALB, g/L (≥ 44.9 vs. < 44.9) 0.694 0.542–0.889 0.004    
GLB, g/L (≥ 30.5 vs. < 30.5) 1.594 1.242–2.047 < 0.001    
Cholesterol, mmol/L (≥ 5.12 vs. < 5.12) 0.955 0.747–1.220 0.710    
T lymphocytes, ×109 (≥ 1.8 vs. < 1.8) 0.913 0.714–1.167 0.468    
Monocytes, ×109 (≥ 0.4 vs. < 0.4) 1.431 1.118–1.832 0.004    
Pathology (Differentiated vs. Undifferentiated 0.410 0.153–1.101 0.077    
Cranial nerve injury (Absent vs. Present) 1.075 0.666–1.736 0.767    
EBV-DNA, copies/ml    < 0.001    < 0.001
  < 1000 1.000 1.000   1.000 1.000  
 1000–9999 1.955 1.349–2.832 < 0.001 1.521 1.045–2.215 0.029
 10,000–99,999 2.757 1.959–3.881 < 0.001 1.822 1.277–2.601 0.001
 100,000–999,999 4.569 3.147–6.631 < 0.001 2.706 1.829–4.004 < 0.001
  ≥ 1,000,000 7.451 4.221–13.151 < 0.001 4.764 1.829–8.533 < 0.001
Treatment method     0.040   
 Radiotherapy 1.000 1.000     
 CCRT 1.064 0.639–1.773 0.811    
 Neo + Radiotherapy 0.188 0.834–2.521 0.188    
 Neo + CCRT 0.752 0.426–1.325 < 0.001    
Radiotherapy technology (IMRT + 3DCRT vs. CRT) 0.745 0.378–1.471 0.397    
T category    0.021    
 1 1.000 1.000     
 2 3.190 1.269–8.020 0.014    
 3 3.752 1.538–9.157 0.004    
 4 3.966 1.596–9.856 0.003    
N category    < 0.001    < 0.001
 0 1.000 1.000   1.000 1.000  
 1 1.731 0.928–3.230 0.085 1.432 0.765–2.681 0.262
 2 3.017 1.638–5.558 < 0.001 2.149 1.156–3.995 0.016
 3 5.987 3.281–10.925 < 0.001 3.613 1.947–6.704 < 0.001
 4 6.310 3.079–12.933 < 0.001 3.629 1.742–7.559 0.001
  1. Abbreviations: SMFS skeletal metastasis-free survival, WBCs white blood cells, HGB hemoglobin, GLB globulin, ALB albumin, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRP C-reactive protein, GGT gamma glutamyl transpeptidase, EBV-DNA Epstein-Barr virus DNA, Undifferentiated undifferentiated non-keratinizing carcinoma, Differentiated, differentiated carcinoma
\